ESTRO 2025 - Abstract Book

S1194

Clinical – Lower GI

ESTRO 2025

Conclusion: For patients with MRI-defined high risk LARC, low rates of CRM involvement and 36 month loco-regional failure were observed.The addition of irinotecan to CRT was associated with decreased radiotherapy and chemotherapy compliance and a higher rate of adverse events.There is no evidence of a difference in the pCR rate,36 month loco regional recurrence free or disease-free survival.

Keywords: Radiotherapy, Chemotherapy, Rectal Cancer